Please wait
Healthcare · Drug Manufacturers - General · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
₦939T
2.0%
30.17
Current price
₦389,700.00
0.0% todayUpdated 3 min ago
Open
₦391,845.00
Previous close
₦389,700.00
Day range
₦387,540.00 – ₦396,225.00
Volume
N/A
30.2x P/E
Awaiting filing
2.0% yield
65/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for JNJ, with its range and direction at a glance.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Investors usually follow JNJ for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 74/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
₦8.3T
TTM (2026-06-30)
ROE
25.7%
Return on equity
ROA
8.6%
Return on assets
Debt / equity
0.58
Lower is usually safer.
P/B ratio
7.36
Useful for book value support.
Dividend yield
2.0%
Current income signal.
84/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦399,225.00
Analyst view
Buy
Analyst target
₦408,750.00
Forecast refresh
Updated just now
Quality score
73
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
₦1,860.00
2024-11-26
Payment: TBA | Qualification: 2024-11-26 | Yield at declaration: N/A
₦1,860.00
2024-08-27
Payment: TBA | Qualification: 2024-08-27 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+2.3% across the latest saved price window.
Volatility
Low
Beta is 0.23. Price has historically moved more calmly than the wider market.
52-week position
85% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
local manufacturing / import substitution
JNJ may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
JNJ may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
JNJ may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
JNJ may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
JNJ may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
increased manufacturing capacity
JNJ may also move because the HEALTHCARE sector may benefit from increased manufacturing capacity. Confidence 53%.
Neimeth's expansion and completion of a pharmaceutical manufacturing facility will increase production capacity within the healthcare sector.
Halal certification adoption
JNJ may also move because the HEALTHCARE sector may benefit from halal certification adoption. Confidence 49%.
Halal certification can increase consumer confidence and market access where Halal-compliant products are important, supporting sector trust and accessibility.
JNJ
Johnson & Johnson
Price: ₦389,700.00
P/E: 30.174215
Yield: 2.0%
ABBV
AbbVie Inc.
Price: ₦375,135.00
P/E: 70.44788
Yield: 2.8%
ABT
Abbott Laboratories
Price: ₦164,580.00
P/E: 35.62338
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: ₦259,432.50
P/E: 30.026909
Yield: 0.0%
Industry
Drug Manufacturers - General
Employees
138200
Exchange
NYQ
Ticker
JNJ
